Minerva Neurosciences, Inc.
NERV evidence brief
What we can confirm
- Market Cap:
- $198.2M
What it means
What to watch
Prepared research question
What matters most for NERV—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NERV
Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company developing roluperidone for negative symptoms of schizophrenia, with no approved products or product revenue to date.
Key risk: No product revenue
Market Cap
$198.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Minerva Neurosciences, Inc..
Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company developing roluperidone for negative symptoms of schizophrenia, with no approved products or product revenue to date.
- Cash & equivalents of $24.7M as of 2026-06-30 [sec].
- Net income of $17.5M as of 2026-06-30 [sec].
- Shareholders' equity of -$213.3M as of 2026-06-30 [sec].
- Accumulated deficit of approximately $796.7 million as of June 30, 2026 [sec_mda · as of 2026-08-07].
- Phase 3 trial (C19) for roluperidone in negative symptoms of schizophrenia; topline efficacy results expected in the second half of 2027 and relapse assessment data in the second half of 2028 [sec_mda · as of 2026-08-07].
What works
- Roluperidone is in Phase 3 development for negative symptoms of schizophrenia, a large market with few approved treatments [pipeline].
- The company has a royalty stream from Janssen on potential future worldwide sales of seltorexant, with no further financial obligations [sec_mda · as of 2026-08-07].
- As of June 30, 2026, the company reported $75.4 million in cash, cash equivalents, marketable securities and restricted cash, which management believes will fund operations for the next 12 months [sec_mda · as of 2026-08-07].
What to weigh
- The company has no approved products and has never generated product revenue; it may never achieve profitability [sec_mda · as of 2026-08-07].
- Accumulated deficit was approximately $796.7 million as of June 30, 2026, and net losses are expected to continue [sec_mda · as of 2026-08-07].
- Clinical and administrative costs are expected to increase as the Phase 3 trial of roluperidone progresses [sec_mda · as of 2026-08-07].
- Shareholders' equity is deeply negative at -$213.3M as of 2026-06-30 [sec].
From the filings
Quoted directly from source documents.
No approved products or product revenue
“We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we may never generate product revenue or achieve profitability.”
SEC MD&A · August 7, 2026
Phase 3 trial for roluperidone and expected timelines
“We currently expect topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028.”
SEC MD&A · August 7, 2026
Accumulated deficit
“had an accumulated deficit of approximately $796.7 million.”
SEC MD&A · August 7, 2026
Cash position and runway
“As of June 30, 2026, we had approximately $75.4 million in cash, cash equivalents, marketable securities and restricted cash, which we believe will be sufficient to meet our operating commitments for the next 12 months”
SEC MD&A · August 7, 2026
Catalyst timeline
- 2026-04-23 · Phase 3 Start for Roluperidone — A 12-week randomized, double-blind, placebo-controlled monotherapy study evaluating efficacy on negative symptoms in schizophrenia, followed by a 52-week relapse assessment phase.
Risks & what to watch (4)›
Key risks
- No product revenue — No approved products or revenue from product sales; may never achieve profitability [sec_mda · as of 2026-08-07].
- Deeply negative equity — Shareholders' equity of -$213.3M as of 2026-06-30 indicates severe financial distress [sec].
- Clinical trial uncertainty — Phase 3 roluperidone trial may fail; topline results not expected until H2 2027 [sec_mda · as of 2026-08-07].
- Cash runway limited — $75.4M cash as of June 30, 2026 expected to fund only ~12 months of operations [sec_mda · as of 2026-08-07].
What to watch
- Topline efficacy results from the Phase 3 roluperidone trial, expected in the second half of 2027 [sec_mda · as of 2026-08-07].
- Relapse assessment data from the same trial, expected in the second half of 2028 [sec_mda · as of 2026-08-07].
- Cash runway and potential need for additional financing as clinical costs increase [sec_mda · as of 2026-08-07].
- Any updates on the seltorexant royalty stream from Janssen [sec_mda · as of 2026-08-07].
Sources: Catalysts · Pipeline · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Minerva Neurosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Minerva Neurosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of Apr 30, 2026- % of float
- 2.8%
- Days to cover
- 2.9
- Shares short
- 1,156,257
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NERV short interestGovernance
Frequently asked questions
What is the AI investment thesis for Minerva Neurosciences, Inc.?
Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company developing roluperidone for negative symptoms of schizophrenia, with no approved products or product revenue to date.
Who is the CEO of Minerva Neurosciences, Inc.?
Dr. Remy Luthringer Ph.D. is the chief executive officer of Minerva Neurosciences, Inc. (NERV).
Where is Minerva Neurosciences, Inc. headquartered?
Minerva Neurosciences, Inc. (NERV) is headquartered in Burlington, MA, United States.
What therapeutic areas does Minerva Neurosciences, Inc. focus on?
Minerva Neurosciences, Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.